Linda Mileshkin

Impact of COVID-19 on Cancer Service Delivery; a follow up international survey of oncology clinicians

Grace Chazan, Fanny Franchini, Marliese Alexander, Susana Banerjee, Linda Mileshkin, Prunella Blinman, Rob Zielinski, Deme Karikios, Nick Pavlakis, Solange Peters, Florian Lordick, David Ball, Gavin Wright, Maarten IJzerman, Benjamin J Solomon

Journal article  |  2021  |  ESMO Open

Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274).

Linda R Mileshkin, Kathleen N Moore, Elizabeth Barnes, Val Gebski, Kailash Narayan, Nathan Bradshaw, Yeh Chen Lee, Katrina Diamante, Anthony W Fyles, William Small, David K Gaffney, Pearly Khaw, Susan Brooks, J Spencer Thompson, Warner King Huh, Matthew Carlson, Cara Amanda Mathews, Danny Rischin, Martin R Stockler, Bradley J Monk

Conference Proceedings  |  2021  |  Journal of Clinical Oncology

LBA3 Background: Cervical cancer is a common cause of cancer-related death among women worldwide. Standard treatment for locally ..

REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer

Katrin M Sjoquist, David Espinoza, Linda Mileshkin, Sumitra Ananda, Catherine Shannon, Sonia Yip, Jeffrey Goh, David Bowtell, Michelle Harrison, Michael L Friedlander

Journal article  |  2021  |  GYNECOLOGIC ONCOLOGY

BACKGROUND: The primary aim of this study was to evaluate the activity of intraperitoneal bevacizumab (IP-bev) in delaying re-accu..

Living with and beyond metastatic non-small cell lung cancer: the survivorship experience for people treated with immunotherapy or targeted therapy

Julia Lai-Kwon, Sarah Heynemann, Jacinthe Flore, Haryana Dhillon, Mary Duffy, John Burke, Lisa Briggs, Lillian Leigh, Linda Mileshkin, Benjamin Solomon, David Ball, Renata Kokanovic, Michael Jefford

Journal article  |  2021  |  JOURNAL OF CANCER SURVIVORSHIP

PURPOSE: Immunotherapy (IT) and targeted therapy (TT) have improved survival for some patients with metastatic non-small cell lung..

Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial

Cathalijne CB Post, Stephanie M de Boer, Melanie E Powell, Linda Mileshkin, Dionyssios Katsaros, Paul Bessette, Christine Haie-Meder, Nelleke PB Ottevanger, Jonathan A Ledermann, Pearly Khaw, Romerai D'Amico, Anthony Fyles, Marie Helene Baron, Henry C Kitchener, Hans W Nijman, Ludy CHW Lutgens, Susan Brooks, Ina M Jurgenliemk-Schulz, Amanda Feeney, Geraldine Goss, et al.

Journal article  |  2021  |  INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

PURPOSE: The survival results of the PORTEC-3 trial showed a significant improvement in both overall and failure-free survival wit..

FAPI PET/CT: Will It End the Hegemony of F-18-FDG in Oncology?

Rodney J Hicks, Peter J Roselt, Kumarswamy G Kallur, Richard W Tothill, Linda Mileshkin

Journal article  |  2021  |  JOURNAL OF NUCLEAR MEDICINE

For over 40 years, 18F-FDG has been the dominant PET tracer in neurology, cardiology, inflammatory diseases, and, most particularl..

P39.06 Surviving Metastatic Non-Small Cell Lung Cancer – Experience and Supportive Care Needs of Patients Receiving Novel Therapies

S Heynemann, J Lai-Kwon, J Flore, H Dhillon, M Duffy, J Burke, L Briggs, L Leigh, L Mileshkin, B Solomon, D Ball, R Kokanovic, M Jefford

Conference Proceedings  |  2021  |  Journal of Thoracic Oncology

Understanding the Feasibility of Patient Reported Outcomes

K Gough, N Moloczij, A Kotevski, M Duffy, D Ball, B Solomon, L Mileshkin, A Drosdowsky, T Koproski, M Krishnasamy

Journal article  |  2021  |  JOURNAL OF THORACIC ONCOLOGY

Surviving Metastatic Non-Small Cell Lung Cancer - Experience and Supportive Care Needs of Patients Receiving Novel Therapies

S Heynemann, J Lai-Kwon, J Flore, H Dhillon, M Duffy, J Burke, L Briggs, L Leigh, L Mileshkin, B Solomon, D Ball, R Kokanovic, M Jefford

Conference Proceedings  |  2021  |  JOURNAL OF THORACIC ONCOLOGY

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

Eun Young Kang, Dane Cheasley, Cecile LePage, Matthew J Wakefield, Michelle da Cunha Torres, Simone Rowley, Carolina Salazar, Zhongyue Xing, Prue Allan, David DL Bowtell, Anne-Marie Mes-Masson, Diane M Provencher, Kurosh Rahimi, Linda E Kelemen, Peter A Fasching, Jennifer A Doherty, Marc T Goodman, Ellen L Goode, Suha Deen, Paul DP Pharoah, et al.

Conference Proceedings  |  2021  |  MODERN PATHOLOGY

TP53 mutations are implicated in the progression of mucinous borderline tumors (MBOT) to mucinous ovarian carcinomas (MOC). Optimi..